Compare BGSF & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BGSF | TIL |
|---|---|---|
| Founded | 2007 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.8M | 74.7M |
| IPO Year | 2013 | 2021 |
| Metric | BGSF | TIL |
|---|---|---|
| Price | $6.09 | $8.42 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 3 |
| Target Price | $9.00 | ★ $125.00 |
| AVG Volume (30 Days) | ★ 23.2K | 21.1K |
| Earning Date | 03-11-2026 | 05-12-2026 |
| Dividend Yield | ★ 33.06% | N/A |
| EPS Growth | ★ 67.37 | 52.54 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $272,499,000.00 | N/A |
| Revenue This Year | $4.67 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.91 | $5.67 |
| 52 Week High | $8.20 | $42.75 |
| Indicator | BGSF | TIL |
|---|---|---|
| Relative Strength Index (RSI) | 52.98 | 48.96 |
| Support Level | $5.93 | $8.14 |
| Resistance Level | $6.38 | $9.27 |
| Average True Range (ATR) | 0.26 | 0.45 |
| MACD | -0.05 | -0.04 |
| Stochastic Oscillator | 33.72 | 36.18 |
BGSF Inc is a national provider of consulting, managed services, and professional workforce solutions. two segments: Property Management and Professional. In the Property Management segment is a provider of office and maintenance talent. The Professional segment provides IT professionals with expertise in SAP, Workday, Peoplesoft, Hyperion, Oracle, One Stream, cyber, project management, managed services, and other IT workforce solutions to client partners on a national basis. The group generates the majority of its revenue from the Professional segment.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.